Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 16/20 | 0.60 |
| ▸ | INSR | P06213 | 8/20 | 0.60 |
| ▸ | IGF1R | P08069 | 7/20 | 0.60 |
| ▸ | EGFR | P00533 | 6/20 | 0.60 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.60 |
| ▸ | PLK4 | O00444 | 2/20 | 0.60 |
| ▸ | GAK | O14976 | 2/20 | 0.60 |
| ▸ | ERN1 | O75460 | 2/20 | 0.60 |
| ▸ | STK10 | O94804 | 2/20 | 0.60 |
| ▸ | ABL1 | P00519 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.60 |
| ▸ | FES | P07332 | 2/20 | 0.60 |
| ▸ | YES1 | P07947 | 2/20 | 0.60 |
| ▸ | HCK | P08631 | 2/20 | 0.60 |
| ▸ | ROS1 | P08922 | 2/20 | 0.60 |
| ▸ | FER | P16591 | 2/20 | 0.60 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.60 |
| ▸ | LTK | P29376 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14857729 | 0.88 | ALK (0.61) | ALKINSRIGF1REGFRBMPR1B | |
| SCHEMBL29015712 | 0.83 | EGFR (0.49) | ALKINSRIGF1REGFRBMPR1B | |
| SCHEMBL1376839 | 0.83 | ZAP70 (0.47) | ALKINSRIGF1REGFRBMPR1B | |
| SCHEMBL29015781 | 0.81 | ALK (0.47) | ALKINSRIGF1REGFRBMPR1B | |
| SCHEMBL25951796 | 0.78 | ALK (0.54) | ALKINSRIGF1REGFRBMPR1B | |
| SCHEMBL29015756 | 0.75 | EGFR (0.44) | ALKINSRIGF1REGFRBMPR1B | |
| Tae-684 SCHEMBL282775 | 0.75 | ALK (1.00) | ALKINSRIGF1REGFRBMPR1B | |
| Tae-684 SCHEMBL29641017 | 0.75 | ALK (1.00) | ALKINSRIGF1REGFRBMPR1B | |
| SCHEMBL18338691 | 0.74 | ALK (0.39) | ALKINSRIGF1REGFRBMPR1B | |
| SCHEMBL1493583 | 0.74 | ALK (0.41) | ALKINSREGFRROS1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | ALK 1482/4885INSR 3900/4885IGF1R 1411/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | ALK 1482/4885INSR 3900/4885IGF1R 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.